home / stock / oyst / oyst news

OYST News and Press, Oyster Point Pharma Inc. From 12/29/20

Stock Information
Company Name: Oyster Point Pharma Inc.
Stock Symbol: OYST
Market: NASDAQ
Website: oysterpointrx.com
Menu
OYST OYST Quote OYST Short OYST News OYST Articles OYST Message Board
Get OYST Alerts

News, Short Squeeze, Breakout and More Instantly...
OYST - Oyster Point Pharma to Participate in the 39th Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...
OYST - Oyster Point Pharma files US application for its lead program in dry eye disease

Oyster Point Pharma (OYST) has submitted a marketing application to the FDA seeking approval for its lead candidate, OC-01 (varenicline) nasal spray for the treatment of signs and symptoms of dry eye disease.The submission is supported by safety and efficacy results from the Phase 3 ONSE...

OYST - Oyster Point Pharma Submits New Drug Application to the U.S. Food and Drug Administration for OC-01 (varenicline) Nasal Spray for the Treatment of Signs and Symptoms of Dry Eye Disease

PRINCETON, N.J., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced it...

OYST - Oyster Point Pharma Strengthens Executive Leadership Team with the Appointment of Chief Medical and Chief Scientific Officers

PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...
OYST - Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)

PRINCETON, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced it...

OYST - Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced th...

OYST - Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting

PRINCETON, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced ne...
OYST - Oyster Point Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

The following slide deck was published by Oyster Point Pharma, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Oyster Point Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

OYST - Oyster Point Pharma, Inc. (OYST) Q3 2020 Earnings Call Transcript

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q3 2020 Earnings Call Nov 05, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q3 2020 Earnings Call Transcript...

OYST - Oyster Point Pharma EPS beats by $0.11

Oyster Point Pharma (OYST): Q3 GAAP EPS of -$0.63 beats by $0.11.Cash and cash equivalents of $214.3M.Press Release For further details see: Oyster Point Pharma EPS beats by $0.11

Previous 10 Next 10